EDN1, endothelin 1, 1906

N. diseases: 679; N. variants: 23
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE We assessed the role of endothelin-1, acting through endothelin A (ET<sub>A</sub> ) receptors, in modulating the central and peripheral cardiovascular responses to exercise in patients with hypertension via local antagonism of these receptors during exercise. 31705661 2020
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 AlteredExpression group BEFREE Opposite alterations of endothelin-1 in lung and pulmonary artery mirror gene expression of bone morphogenetic protein receptor 2 in experimental pulmonary hypertension. 31012341 2020
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Endothelin 1 Is Associated with Heart Failure Hospitalization and Long-Term Mortality in Patients with Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension. 31514181 2020
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Endothelin-1 (ET-1) is a powerful vasoconstrictor peptide considered to be causally implicated in hypertension and the development of cardiovascular disease. 31630572 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Endothelin-1 (ET-1), as it functions as a neuromodulator, has been associated with hypertension in chronic intermittent hypoxia (CIH) which attribute to enhanced carotid body sensibility to hypoxia. 30579678 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE The most potent vasoconstrictor, endothelin-1 and its receptors, endothelin receptor A (EDNRA) and endothelin receptor B (EDNRB) are involved in hypertension. 31150867 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Mφ and ET-1 may play an important role in BP control and potentially have a critical role as a therapeutic target in hypertension. 30657897 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Our findings define novel molecular mechanism involving interplay between microparticles, the ET-1 system and endothelial cell pro-inflammatory and redox signalling, which may be important in cardiovascular toxicity and hypertension associated with VEGFi anti-cancer treatment. 30753341 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE The angiotensin II AT<sub>1</sub> and the endothelin 1 ET<sub>A</sub> receptors play a crucial role in the pathogenesis of cardiovascular diseases like hypertension, heart failure, stroke, pulmonary hypertension, and cardiac hypertrophy. 30851407 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Endothelin-1 (ET-1) is a potential contributor to sex differences in the pathophysiology of hypertension. 30606254 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 AlteredExpression group BEFREE This resulted in a rapid onset of hypertension, a decrease in eNOS expression, and an increase in endothelin-1 plasma levels, with all mice dying within 5 wk. 31196980 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Endothelin-1/nitric oxide balance and HOMA index in children with excess weight and hypertension: a pathophysiological model of hypertension. 30923371 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 GeneticVariation group BEFREE Our results indicated that the mechanisms of hypertension in AMA may differ from those in young individuals from the point of VEGF-endothelin-1 system. 31272714 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Logistic regression models indicated that hypertension duration (P<0.001, 95% CI: 0.962-0.988) and ET-1 level (P<0.001, 95% CI: 1.144-1.278) were significantly associated with HRP. 30651821 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 AlteredExpression group BEFREE In addition, RhoA expression was downregulated when oxidative stress was attenuated by DPI, while Y-27632 decreased the expression of endothelin-1, which is overexpressed in the vascular wall during hypertension. 30609027 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Endothelin-1 (ET-1), N-terminal fragment of pro-atrial natriuretic peptide (NTpro-ANP), and tumour necrosis factor alpha (TNF-α) in children with primary hypertension and hypertension of renal origin. 30359461 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE In summary, in hypertension, pioglitazone shifts the vascular ET<sub>A</sub>/ET<sub>B</sub> ratio, reduces ROS/COX-2 activation and increases NO availability; these changes explain the effect of ET-1 decreasing phenylephrine-induced contraction. 31712626 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE These findings highlight the role of endothelin-1 in driving biventricular remodeling secondary to RV hypertension and suggest that early therapy with an endothelin-1 receptor blocker may be beneficial in attenuating biventricular remodeling but that late therapy is also effective. 29446710 2018
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE It is believed that ET-1 plays an important role in pathogenesis of hypertension, and cardiovascular diseases; therefore, research in order to limit ET-1-mediated action is still in progress. 29738719 2018
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Magnesium attenuates endothelin-1-induced vasoreactivity and enhances vasodilatation in mouse pulmonary arteries: Modulation by chronic hypoxic pulmonary hypertension. 29363240 2018
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Ambrisentan is a highly selective endothelin-1 type A receptor antagonist indicated for use in the treatment of pulmonary hypertension. 29289894 2018
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE The aim of this study was to investigate if hypertension has an effect on vasoconstrictive receptor responses to endothelin 1, sarafotoxin 6c and angiotensin II after stroke by inducing transient middle cerebral artery occlusion in spontaneously hypertensive rats and Wistar-Kyoto rats using the wire-myograph. 29190633 2018
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Thus, loss of ET-1-dependent natriuresis may account for sodium retention during stress and may predispose retainers to renal diseases such as hypertension and kidney disease. 29246686 2018
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE The goal of this study is to elucidate the role of Endothelin-1 (ET-1) in aortic stiffening-induced hypertension through ET<sub>A</sub> receptor activation. 29449619 2018
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE The present study was designed to test the hypothesis that VEGF receptor inhibitor treatment leads to hypertension through decreased renal medullary formation of NO and endothelin-1. 29311252 2018